Biological
Nemvaleukin alfa
Nemvaleukin alfa is a biological therapy with 2 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
2
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(50%)
Results Posted
100%(1 trials)
Phase Distribution
Ph phase_2
1
50%
Ph phase_1
1
50%
Phase Distribution
1
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 2Efficacy & side effects
1(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
2
all time
Status Distribution
Active(1)
Completed(1)
Detailed Status
Active, not recruiting1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
2
Active
1
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (50.0%)
Phase 21 (50.0%)
Trials by Status
active_not_recruiting150%
completed150%
Recent Activity
1 active trials
Showing 2 of 2
completedphase_2
A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer
NCT04144517
active_not_recruitingphase_1
Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)
NCT04592653
Clinical Trials (2)
Showing 2 of 2 trials
NCT04144517Phase 2
A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer
NCT04592653Phase 1
Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)
All 2 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 2